CA2937430A1 - Compounds - Google Patents

Info

Publication number

CA2937430A1

CA2937430A1 CA2937430A CA2937430A CA2937430A1 CA 2937430 A1 CA2937430 A1 CA 2937430A1 CA 2937430 A CA2937430 A CA 2937430A CA 2937430 A CA2937430 A CA 2937430A CA 2937430 A1 CA2937430 A1 CA 2937430A1

Authority

CA

Canada

Prior art keywords

mmol

methanone

amino

compound

pharmaceutically acceptable

Prior art date

2014-01-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims abstract description 300
• 208000018737 Parkinson disease Diseases 0.000 claims abstract description 59
• 238000011282 treatment Methods 0.000 claims abstract description 58
• 238000000034 method Methods 0.000 claims abstract description 48
• 150000003839 salts Chemical class 0.000 claims description 121
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 43
• 229910052757 nitrogen Inorganic materials 0.000 claims description 33
• 239000002253 acid Substances 0.000 claims description 32
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 29
• 125000001424 substituent group Chemical group 0.000 claims description 27
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 26
• 125000000623 heterocyclic group Chemical group 0.000 claims description 25
• 229910052739 hydrogen Inorganic materials 0.000 claims description 23
• 239000008194 pharmaceutical composition Substances 0.000 claims description 22
• 239000003814 drug Substances 0.000 claims description 17
• 238000004519 manufacturing process Methods 0.000 claims description 12
• 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 7
• 229910052731 fluorine Inorganic materials 0.000 claims description 6
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
• 239000012458 free base Substances 0.000 claims description 5
• 125000004193 piperazinyl group Chemical group 0.000 claims description 4
• 125000002757 morpholinyl group Chemical group 0.000 claims description 2
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 7
• 125000001475 halogen functional group Chemical group 0.000 claims 4
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
• 208000034968 autosomal dominant susceptibility to Parkinson disease 13 Diseases 0.000 claims 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
• ZLLCVOJWNDZXIO-UHFFFAOYSA-N n-propyl-4-[[4-(3,3,3-trifluoropropyl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NCCC)=CC=C1NC1=NC(CCC(F)(F)F)=C(C=CN2)C2=N1 ZLLCVOJWNDZXIO-UHFFFAOYSA-N 0.000 claims 1
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
• 125000003386 piperidinyl group Chemical group 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 152
• 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract description 90
• 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 abstract description 86
• 230000000694 effects Effects 0.000 abstract description 21
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract description 19
• 208000024827 Alzheimer disease Diseases 0.000 abstract description 17
• 238000002360 preparation method Methods 0.000 abstract description 7
• 230000008569 process Effects 0.000 abstract description 7
• 230000006806 disease prevention Effects 0.000 abstract 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 252
• 239000000243 solution Substances 0.000 description 136
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 123
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 122
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 107
• 239000007787 solid Substances 0.000 description 98
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 91
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 91
• -1 methylethyl Chemical group 0.000 description 88
• 238000005160 1H NMR spectroscopy Methods 0.000 description 77
• 239000012044 organic layer Substances 0.000 description 71
• OFRMASLPWOMYHN-UHFFFAOYSA-N 1-[3-methoxy-4-[[6-(2-propan-2-ylsulfonylanilino)-7H-purin-2-yl]amino]phenyl]piperidin-4-ol Chemical group COc1cc(ccc1Nc1nc(Nc2ccccc2S(=O)(=O)C(C)C)c2[nH]cnc2n1)N1CCC(O)CC1 OFRMASLPWOMYHN-UHFFFAOYSA-N 0.000 description 67
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 61
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 58
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 55
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 54
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 50
• 201000010099 disease Diseases 0.000 description 47
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 45
• BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 45
• 229910052938 sodium sulfate Inorganic materials 0.000 description 45
• 235000011152 sodium sulphate Nutrition 0.000 description 45
• 239000007832 Na2SO4 Substances 0.000 description 44
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 41
• 239000011541 reaction mixture Substances 0.000 description 39
• 239000000741 silica gel Substances 0.000 description 37
• 229910002027 silica gel Inorganic materials 0.000 description 37
• 230000035772 mutation Effects 0.000 description 36
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 36
• 239000002904 solvent Substances 0.000 description 36
• 238000006243 chemical reaction Methods 0.000 description 35
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 34
• 239000000543 intermediate Substances 0.000 description 33
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 32
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 29
• 239000003921 oil Substances 0.000 description 28
• 210000004027 cell Anatomy 0.000 description 27
• 235000019198 oils Nutrition 0.000 description 27
• 238000002953 preparative HPLC Methods 0.000 description 26
• 238000004440 column chromatography Methods 0.000 description 25
• 239000012071 phase Substances 0.000 description 25
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
• LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 24
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 23
• 125000006239 protecting group Chemical group 0.000 description 21
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
• 239000002585 base Substances 0.000 description 19
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
• 201000011240 Frontotemporal dementia Diseases 0.000 description 18
• 239000012267 brine Substances 0.000 description 18
• 229910000027 potassium carbonate Inorganic materials 0.000 description 18
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
• CROCDXCMEKSYHU-UHFFFAOYSA-N 2-chloro-4-ethoxy-7H-pyrrolo[2,3-d]pyrimidine Chemical compound ClC=1N=C(C2=C(N=1)NC=C2)OCC CROCDXCMEKSYHU-UHFFFAOYSA-N 0.000 description 17
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
• 238000003556 assay Methods 0.000 description 17
• JQTMGOLZSBTZMS-UHFFFAOYSA-N 4-methylpiperazine-1-carbaldehyde Chemical compound CN1CCN(C=O)CC1 JQTMGOLZSBTZMS-UHFFFAOYSA-N 0.000 description 16
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
• 239000003153 chemical reaction reagent Substances 0.000 description 16
• 238000004587 chromatography analysis Methods 0.000 description 16
• 239000006184 cosolvent Substances 0.000 description 16
• 125000005843 halogen group Chemical group 0.000 description 16
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
• 239000007821 HATU Substances 0.000 description 15
• 102200092160 rs34637584 Human genes 0.000 description 15
• 229910000104 sodium hydride Inorganic materials 0.000 description 15
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
• 238000007125 Buchwald synthesis reaction Methods 0.000 description 14
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 14
• 125000000217 alkyl group Chemical group 0.000 description 14
• 238000004296 chiral HPLC Methods 0.000 description 14
• 235000011181 potassium carbonates Nutrition 0.000 description 14
• CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 14
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 13
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 12
• 206010012289 Dementia Diseases 0.000 description 12
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 12
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 125000004432 carbon atom Chemical group C* 0.000 description 12
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 12
• 239000003112 inhibitor Substances 0.000 description 12
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
• 238000000746 purification Methods 0.000 description 12
• 239000012453 solvate Substances 0.000 description 12
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
• 239000012312 sodium hydride Substances 0.000 description 11
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
• 229940124786 LRRK2 inhibitor Drugs 0.000 description 10
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
• 150000001412 amines Chemical class 0.000 description 10
• 238000001914 filtration Methods 0.000 description 10
• 230000002265 prevention Effects 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 239000000460 chlorine Substances 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 239000007858 starting material Substances 0.000 description 9
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 8
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
• 238000005481 NMR spectroscopy Methods 0.000 description 8
• 208000027089 Parkinsonian disease Diseases 0.000 description 8
• 206010034010 Parkinsonism Diseases 0.000 description 8
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 8
• 238000003016 alphascreen Methods 0.000 description 8
• 125000004429 atom Chemical group 0.000 description 8
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 8
• 239000003054 catalyst Substances 0.000 description 8
• 208000032839 leukemia Diseases 0.000 description 8
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• OQHQOOLVQDEIGL-UHFFFAOYSA-N 2-methyl-2,7-diazaspiro[4.4]nonane Chemical compound C1N(C)CCC11CNCC1 OQHQOOLVQDEIGL-UHFFFAOYSA-N 0.000 description 7
• 208000032382 Ischaemic stroke Diseases 0.000 description 7
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 7
• 208000030886 Traumatic Brain injury Diseases 0.000 description 7
• 229910021529 ammonia Inorganic materials 0.000 description 7
• 208000010877 cognitive disease Diseases 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 208000027061 mild cognitive impairment Diseases 0.000 description 7
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• AHRQYOSAXZQCIG-UHFFFAOYSA-N pyrimidine-5-carbonitrile Chemical compound N#CC1=C=NC=N[CH]1 AHRQYOSAXZQCIG-UHFFFAOYSA-N 0.000 description 7
• 239000011734 sodium Substances 0.000 description 7
• 208000020431 spinal cord injury Diseases 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 7
• 230000009529 traumatic brain injury Effects 0.000 description 7
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 6
• 208000011231 Crohn disease Diseases 0.000 description 6
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
• 208000015872 Gaucher disease Diseases 0.000 description 6
• 208000015439 Lysosomal storage disease Diseases 0.000 description 6
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 6
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 6
• 230000001594 aberrant effect Effects 0.000 description 6
• 210000000481 breast Anatomy 0.000 description 6
• 210000000349 chromosome Anatomy 0.000 description 6
• 238000005859 coupling reaction Methods 0.000 description 6
• 239000012043 crude product Substances 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 239000000284 extract Substances 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 201000006417 multiple sclerosis Diseases 0.000 description 6
• 229910052763 palladium Inorganic materials 0.000 description 6
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 238000002636 symptomatic treatment Methods 0.000 description 6
• 238000003786 synthesis reaction Methods 0.000 description 6
• 238000012360 testing method Methods 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
• UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 6
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
• VVKKSKQZLBRBBO-UHFFFAOYSA-N 2-chloro-4-ethoxy-5-iodo-7H-pyrrolo[2,3-d]pyrimidine Chemical compound ClC=1N=C(C2=C(N=1)NC=C2I)OCC VVKKSKQZLBRBBO-UHFFFAOYSA-N 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 208000009829 Lewy Body Disease Diseases 0.000 description 5
• 201000002832 Lewy body dementia Diseases 0.000 description 5
• 108091000080 Phosphotransferase Proteins 0.000 description 5
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
• 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 5
• 201000004810 Vascular dementia Diseases 0.000 description 5
• 125000003545 alkoxy group Chemical group 0.000 description 5
• 239000011324 bead Substances 0.000 description 5
• 230000001413 cellular effect Effects 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 238000007796 conventional method Methods 0.000 description 5
• 230000007547 defect Effects 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 238000004128 high performance liquid chromatography Methods 0.000 description 5
• 229910052742 iron Inorganic materials 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 230000007074 memory dysfunction Effects 0.000 description 5
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
• 230000001537 neural effect Effects 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 230000026731 phosphorylation Effects 0.000 description 5
• 238000006366 phosphorylation reaction Methods 0.000 description 5
• 102000020233 phosphotransferase Human genes 0.000 description 5
• 102000004169 proteins and genes Human genes 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• KNCZGHQEKWOGHY-UHFFFAOYSA-N (3-fluoro-4-nitrophenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 KNCZGHQEKWOGHY-UHFFFAOYSA-N 0.000 description 4
• GPRUBQPFDXFIJN-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-morpholin-4-ylmethanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2CCOCC2)=C1 GPRUBQPFDXFIJN-UHFFFAOYSA-N 0.000 description 4
• GXVIPZJXBXDOHA-UHFFFAOYSA-N 2-chloro-3-methoxy-4-nitrobenzoic acid Chemical compound ClC1=C(C(=O)O)C=CC(=C1OC)[N+](=O)[O-] GXVIPZJXBXDOHA-UHFFFAOYSA-N 0.000 description 4
• LSIIXEGXZZZUTM-UHFFFAOYSA-N 3-(cyclopropylmethoxy)-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(OCC2CC2)=C1 LSIIXEGXZZZUTM-UHFFFAOYSA-N 0.000 description 4
• IRJNTPHQQOHBGU-UHFFFAOYSA-N 3-(difluoromethoxy)-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(OC(F)F)=C1 IRJNTPHQQOHBGU-UHFFFAOYSA-N 0.000 description 4
• PWURRRRGLCVBMX-UHFFFAOYSA-N 3-methoxy-4-nitrobenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1[N+]([O-])=O PWURRRRGLCVBMX-UHFFFAOYSA-N 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 208000012661 Dyskinesia Diseases 0.000 description 4
• 208000004332 Evans syndrome Diseases 0.000 description 4
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 4
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
• WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
• 206010025323 Lymphomas Diseases 0.000 description 4
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• 201000002481 Myositis Diseases 0.000 description 4
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 4
• 208000021386 Sjogren Syndrome Diseases 0.000 description 4
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• 230000003281 allosteric effect Effects 0.000 description 4
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 239000004305 biphenyl Substances 0.000 description 4
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
• 229910000024 caesium carbonate Inorganic materials 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 125000001188 haloalkyl group Chemical group 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• 150000004677 hydrates Chemical class 0.000 description 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 208000020816 lung neoplasm Diseases 0.000 description 4
• XJAGTAYJYBVTIH-UHFFFAOYSA-N methyl 3-(cyclopropylmethoxy)-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(OCC2CC2)=C1 XJAGTAYJYBVTIH-UHFFFAOYSA-N 0.000 description 4
• IXUCYGQTKDSONM-UHFFFAOYSA-N methyl 3-(difluoromethoxy)-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(OC(F)F)=C1 IXUCYGQTKDSONM-UHFFFAOYSA-N 0.000 description 4
• QSRRZKPKHJHIRB-UHFFFAOYSA-N methyl 4-[(2,5-dichloro-4-methylthiophen-3-yl)sulfonylamino]-2-hydroxybenzoate Chemical compound C1=C(O)C(C(=O)OC)=CC=C1NS(=O)(=O)C1=C(Cl)SC(Cl)=C1C QSRRZKPKHJHIRB-UHFFFAOYSA-N 0.000 description 4
• 208000008795 neuromyelitis optica Diseases 0.000 description 4
• 239000012074 organic phase Substances 0.000 description 4
• 239000008188 pellet Substances 0.000 description 4
• 235000015320 potassium carbonate Nutrition 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 102200092223 rs33939927 Human genes 0.000 description 4
• 208000017520 skin disease Diseases 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• UFVKIYCXXSGEHM-UHFFFAOYSA-N (3-ethoxy-4-nitrophenyl)-morpholin-4-ylmethanone Chemical compound C(C)OC=1C=C(C=CC=1[N+](=O)[O-])C(=O)N1CCOCC1 UFVKIYCXXSGEHM-UHFFFAOYSA-N 0.000 description 3
• DVWPBDJBUIJVSI-UHFFFAOYSA-N (3-fluoro-4-nitrophenyl)-morpholin-4-ylmethanone Chemical compound C1=C(F)C([N+](=O)[O-])=CC=C1C(=O)N1CCOCC1 DVWPBDJBUIJVSI-UHFFFAOYSA-N 0.000 description 3
• VJRGJYUEJPBPEN-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-(4-fluoropiperidin-1-yl)methanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2CCC(F)CC2)=C1 VJRGJYUEJPBPEN-UHFFFAOYSA-N 0.000 description 3
• MMGJIPZQQGLXAF-SECBINFHSA-N (4-amino-3-methoxyphenyl)-[(3r)-3-methylmorpholin-4-yl]methanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2[C@@H](COCC2)C)=C1 MMGJIPZQQGLXAF-SECBINFHSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• SILRXJAFPBVTIU-UHFFFAOYSA-N ClC=1N=C(C2=C(N=1)NC=C2)OCC1CC1 Chemical compound ClC=1N=C(C2=C(N=1)NC=C2)OCC1CC1 SILRXJAFPBVTIU-UHFFFAOYSA-N 0.000 description 3
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
• 206010024229 Leprosy Diseases 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
• SJTGNEQZIRYEFF-UHFFFAOYSA-N [3-(dimethylamino)-4-nitrophenyl]-morpholin-4-ylmethanone Chemical compound CN(C=1C=C(C=CC=1[N+](=O)[O-])C(=O)N1CCOCC1)C SJTGNEQZIRYEFF-UHFFFAOYSA-N 0.000 description 3
• XCQZSMPJFKRMEC-UHFFFAOYSA-N [3-ethoxy-4-[(4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino]phenyl]-morpholin-4-ylmethanone Chemical compound C(C)OC=1C=C(C=CC=1NC=1N=C(C2=C(N=1)NC=C2)OCC)C(=O)N1CCOCC1 XCQZSMPJFKRMEC-UHFFFAOYSA-N 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 239000004480 active ingredient Substances 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 239000012131 assay buffer Substances 0.000 description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• 238000009833 condensation Methods 0.000 description 3
• 230000005494 condensation Effects 0.000 description 3
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 239000007884 disintegrant Substances 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 206010013663 drug dependence Diseases 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 230000005284 excitation Effects 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• SBPSDEQYWNQMHM-UHFFFAOYSA-N methyl 2-chloro-3-methoxy-4-nitrobenzoate Chemical compound ClC1=C(C(=O)OC)C=CC(=C1OC)[N+](=O)[O-] SBPSDEQYWNQMHM-UHFFFAOYSA-N 0.000 description 3
• CBTDHGHNLNIBQS-UHFFFAOYSA-N morpholin-4-yl-(4-nitro-3-propan-2-yloxyphenyl)methanone Chemical compound C(C)(C)OC=1C=C(C=CC=1[N+](=O)[O-])C(=O)N1CCOCC1 CBTDHGHNLNIBQS-UHFFFAOYSA-N 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 239000008184 oral solid dosage form Substances 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• YYROPELSRYBVMQ-UHFFFAOYSA-N p-toluenesulfonyl chloride Substances CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 3
• 238000002600 positron emission tomography Methods 0.000 description 3
• 239000011347 resin Substances 0.000 description 3
• 229920005989 resin Polymers 0.000 description 3
• 229910052701 rubidium Inorganic materials 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 235000017557 sodium bicarbonate Nutrition 0.000 description 3
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 208000011117 substance-related disease Diseases 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 239000003643 water by type Substances 0.000 description 3
• DISHZSZNLADMLH-SECBINFHSA-N (3-methoxy-4-nitrophenyl)-[(3R)-3-methylmorpholin-4-yl]methanone Chemical compound COC=1C=C(C=CC=1[N+](=O)[O-])C(=O)N1[C@@H](COCC1)C DISHZSZNLADMLH-SECBINFHSA-N 0.000 description 2
• ZBVAADHKVJYWHF-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-[1-(methoxymethyl)-3-azabicyclo[3.1.0]hexan-3-yl]methanone Chemical compound NC1=C(C=C(C=C1)C(=O)N1CC2(CC2C1)COC)OC ZBVAADHKVJYWHF-UHFFFAOYSA-N 0.000 description 2
• FQIPRWUQUGZEON-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2CCC(CC2)N2CCN(C)CC2)=C1 FQIPRWUQUGZEON-UHFFFAOYSA-N 0.000 description 2
• PIILVZKNRZVYSH-UHFFFAOYSA-N (4-amino-3-propan-2-yloxyphenyl)-morpholin-4-ylmethanone Chemical compound C1=C(N)C(OC(C)C)=CC(C(=O)N2CCOCC2)=C1 PIILVZKNRZVYSH-UHFFFAOYSA-N 0.000 description 2
• KMWMHGDGKNFOMV-UHFFFAOYSA-N 2-chloro-3-hydroxy-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(O)=C1Cl KMWMHGDGKNFOMV-UHFFFAOYSA-N 0.000 description 2
• CSXHYQCXIKBLLX-UHFFFAOYSA-N 2-chloro-4-ethoxy-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile Chemical compound ClC=1N=C(C2=C(N=1)NC=C2C#N)OCC CSXHYQCXIKBLLX-UHFFFAOYSA-N 0.000 description 2
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 2
• GXWNSJYVSIJRLS-UHFFFAOYSA-N 6-bromo-8-methylimidazo[1,2-a]pyrazine Chemical compound CC1=NC(Br)=CN2C=CN=C12 GXWNSJYVSIJRLS-UHFFFAOYSA-N 0.000 description 2
• PHOQTUXRQPJPJY-UHFFFAOYSA-O 6-carboxy-2-hydroxy-3-nitrobenzenediazonium Chemical compound C(=O)(O)C1=CC=C(C(=C1[N+]#N)O)[N+](=O)[O-] PHOQTUXRQPJPJY-UHFFFAOYSA-O 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 2
• 108091006109 GTPases Proteins 0.000 description 2
• 101100021877 Homo sapiens LRRK2 gene Proteins 0.000 description 2
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 101150081013 LRRK2 gene Proteins 0.000 description 2
• 102220596654 Leucine-rich repeat serine/threonine-protein kinase 2_R1441C_mutation Human genes 0.000 description 2
• 102220577884 Leucine-rich repeat serine/threonine-protein kinase 2_Y1699C_mutation Human genes 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 108091062154 Mir-205 Proteins 0.000 description 2
• 229920000881 Modified starch Polymers 0.000 description 2
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000012902 Nervous system disease Diseases 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 239000012124 Opti-MEM Substances 0.000 description 2
• WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 229910021120 PdC12 Inorganic materials 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 240000006394 Sorghum bicolor Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000034799 Tauopathies Diseases 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 102000003802 alpha-Synuclein Human genes 0.000 description 2
• 108090000185 alpha-Synuclein Proteins 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 229940077388 benzenesulfonate Drugs 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 125000001246 bromo group Chemical group Br* 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 210000003169 central nervous system Anatomy 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 238000012937 correction Methods 0.000 description 2
• 238000006880 cross-coupling reaction Methods 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
• SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
• GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000003937 drug carrier Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000004064 dysfunction Effects 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 230000006951 hyperphosphorylation Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 229910001629 magnesium chloride Inorganic materials 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• GQJCAQADCPTHKN-UHFFFAOYSA-N methyl 2,2-difluoro-2-fluorosulfonylacetate Chemical compound COC(=O)C(F)(F)S(F)(=O)=O GQJCAQADCPTHKN-UHFFFAOYSA-N 0.000 description 2
• UEGCRFNWTGYVKX-UHFFFAOYSA-N methyl 3-hydroxy-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(O)=C1 UEGCRFNWTGYVKX-UHFFFAOYSA-N 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000002314 neuroinflammatory effect Effects 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• 239000002798 polar solvent Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229920001592 potato starch Polymers 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 239000011435 rock Substances 0.000 description 2
• 102220010566 rs74163686 Human genes 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 229940032147 starch Drugs 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• MRYZPLULYNZMJD-VGMNWLOBSA-N tert-butyl (1s,3s,5s)-3-cyano-2-azabicyclo[3.1.0]hexane-2-carboxylate Chemical compound C1[C@@H](C#N)N(C(=O)OC(C)(C)C)[C@H]2C[C@H]21 MRYZPLULYNZMJD-VGMNWLOBSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 210000001519 tissue Anatomy 0.000 description 2
• 238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 2
• ZQSMZFIOPBRRKZ-SRQIZXRXSA-N (1s,3s,5s)-2-azabicyclo[3.1.0]hexane-3-carbonitrile Chemical compound N1[C@H](C#N)C[C@@H]2C[C@@H]21 ZQSMZFIOPBRRKZ-SRQIZXRXSA-N 0.000 description 1
• VASDEEBNVDJQRB-GAJRHLONSA-N (1s,3s,5s)-2-azabicyclo[3.1.0]hexane-3-carbonitrile;hydrochloride Chemical compound Cl.N1[C@H](C#N)C[C@@H]2C[C@@H]21 VASDEEBNVDJQRB-GAJRHLONSA-N 0.000 description 1
• YDIKCZBMBPOGFT-DIONPBRTSA-N (2s,3r,4s,5s,6r)-2-[5,7-dihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride Chemical compound [Cl-].COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 YDIKCZBMBPOGFT-DIONPBRTSA-N 0.000 description 1
• AKDDPJJPMJXXEF-UHFFFAOYSA-N (3-methoxy-4-nitrophenyl)-(2-oxa-7-azaspiro[3.4]octan-7-yl)methanone Chemical compound COC1=CC(=CC=C1[N+]([O-])=O)C(=O)N1CCC2(COC2)C1 AKDDPJJPMJXXEF-UHFFFAOYSA-N 0.000 description 1
• DISHZSZNLADMLH-VIFPVBQESA-N (3-methoxy-4-nitrophenyl)-[(3S)-3-methylmorpholin-4-yl]methanone Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCOC[C@@H]1C)[N+]([O-])=O DISHZSZNLADMLH-VIFPVBQESA-N 0.000 description 1
• SLTNMZFIUOVGMI-UHFFFAOYSA-N (3-methoxy-4-nitrophenyl)-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCC(CC1)N1CCN(C)CC1)[N+]([O-])=O SLTNMZFIUOVGMI-UHFFFAOYSA-N 0.000 description 1
• MLMBJSUQMNEIFJ-UHFFFAOYSA-N (4-amino-2-fluoro-5-methoxyphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound NC1=CC(=C(C=C1OC)C(=O)N1CCN(CC1)C)F MLMBJSUQMNEIFJ-UHFFFAOYSA-N 0.000 description 1
• ZGEFJQYUWKKSKT-UHFFFAOYSA-N (4-amino-2-fluoro-5-methoxyphenyl)-morpholin-4-ylmethanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2CCOCC2)=C1F ZGEFJQYUWKKSKT-UHFFFAOYSA-N 0.000 description 1
• NRMHMZCGQFWWFL-UHFFFAOYSA-N (4-amino-3-fluorophenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(N)C(F)=C1 NRMHMZCGQFWWFL-UHFFFAOYSA-N 0.000 description 1
• SXIBDSYYUVQGGX-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-(1,3-oxazolidin-3-yl)methanone Chemical compound COC1=C(N)C=CC(=C1)C(=O)N1CCOC1 SXIBDSYYUVQGGX-UHFFFAOYSA-N 0.000 description 1
• ZWSCQQVYRLNBOU-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-(2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2CC3(COC3)C2)=C1 ZWSCQQVYRLNBOU-UHFFFAOYSA-N 0.000 description 1
• PWEMXKRWQYCDSH-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-(2-oxa-7-azaspiro[3.4]octan-7-yl)methanone Chemical compound NC1=C(C=C(C=C1)C(=O)N1CC2(COC2)CC1)OC PWEMXKRWQYCDSH-UHFFFAOYSA-N 0.000 description 1
• ONSLAZXAMOMVKL-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-(6-azaspiro[2.5]octan-6-yl)methanone Chemical compound COC1=C(N)C=CC(=C1)C(=O)N1CCC2(CC2)CC1 ONSLAZXAMOMVKL-UHFFFAOYSA-N 0.000 description 1
• XYNUWQYJZBUQCR-SNVBAGLBSA-N (4-amino-3-methoxyphenyl)-[(2R)-2,4-dimethylpiperazin-1-yl]methanone Chemical compound COC1=C(N)C=CC(=C1)C(=O)N1CCN(C)C[C@H]1C XYNUWQYJZBUQCR-SNVBAGLBSA-N 0.000 description 1
• XKTUTAITYNMIMS-AOOOYVTPSA-N (4-amino-3-methoxyphenyl)-[(2R,6S)-2,6-dimethylmorpholin-4-yl]methanone Chemical compound NC1=C(C=C(C=C1)C(=O)N1C[C@H](O[C@H](C1)C)C)OC XKTUTAITYNMIMS-AOOOYVTPSA-N 0.000 description 1
• XYNUWQYJZBUQCR-JTQLQIEISA-N (4-amino-3-methoxyphenyl)-[(2S)-2,4-dimethylpiperazin-1-yl]methanone Chemical compound COC1=C(N)C=CC(=C1)C(=O)N1CCN(C)C[C@@H]1C XYNUWQYJZBUQCR-JTQLQIEISA-N 0.000 description 1
• MMGJIPZQQGLXAF-VIFPVBQESA-N (4-amino-3-methoxyphenyl)-[(3s)-3-methylmorpholin-4-yl]methanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2[C@H](COCC2)C)=C1 MMGJIPZQQGLXAF-VIFPVBQESA-N 0.000 description 1
• DNUUIHCAKALIEA-UHFFFAOYSA-N (4-amino-3-propan-2-yloxyphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound NC1=C(C=C(C=C1)C(=O)N1CCN(CC1)C)OC(C)C DNUUIHCAKALIEA-UHFFFAOYSA-N 0.000 description 1
• WEHVQIQNGXWTME-UHFFFAOYSA-N (4-aminophenyl)-morpholin-4-ylmethanone Chemical compound C1=CC(N)=CC=C1C(=O)N1CCOCC1 WEHVQIQNGXWTME-UHFFFAOYSA-N 0.000 description 1
• NDYMQOUYJJXCKJ-UHFFFAOYSA-N (4-fluorophenyl)-morpholin-4-ylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)N1CCOCC1 NDYMQOUYJJXCKJ-UHFFFAOYSA-N 0.000 description 1
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
• ARHYWWAJZDAYDJ-UHFFFAOYSA-N 1,2-dimethylpiperazine Chemical compound CC1CNCCN1C ARHYWWAJZDAYDJ-UHFFFAOYSA-N 0.000 description 1
• LBYYDCLPMZOATJ-UHFFFAOYSA-N 1-methoxy-4-methylpiperazine Chemical compound CON1CCN(C)CC1 LBYYDCLPMZOATJ-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• GHXBPCSSQOKKGB-UHFFFAOYSA-N 2,4-dichloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C=CNC2=N1 GHXBPCSSQOKKGB-UHFFFAOYSA-N 0.000 description 1
• KYFXPHPBTUJULU-UHFFFAOYSA-N 2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile Chemical compound COC1=CC=CC=C1NC(C#N)C1=CC=CC=C1OCC1=CC=CC=C1 KYFXPHPBTUJULU-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
• JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
• AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 1
• WAVYWHRLGFPXMJ-UHFFFAOYSA-N 4,6-dichloro-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2C(C)=NNC2=N1 WAVYWHRLGFPXMJ-UHFFFAOYSA-N 0.000 description 1
• SGCJDQPUPGNUIZ-UHFFFAOYSA-N 4-[(4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino]-3-methoxybenzoic acid Chemical compound C(C)OC=1C2=C(N=C(N=1)NC1=C(C=C(C(=O)O)C=C1)OC)NC=C2 SGCJDQPUPGNUIZ-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• YIYBPEDZAUFQLO-UHFFFAOYSA-N 4-amino-3-chlorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1Cl YIYBPEDZAUFQLO-UHFFFAOYSA-N 0.000 description 1
• JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 1
• HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
• WFVOJAADOCCDAK-FQEVSTJZSA-N 4-ethoxy-N-[2-methoxy-4-[[(3S)-3-methylmorpholin-4-yl]methyl]phenyl]-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-2-amine Chemical compound C(C)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)CN1[C@H](COCC1)C)OC)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 WFVOJAADOCCDAK-FQEVSTJZSA-N 0.000 description 1
• UEALKTCRMBVTFN-UHFFFAOYSA-N 4-nitroanthranilic acid Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(O)=O UEALKTCRMBVTFN-UHFFFAOYSA-N 0.000 description 1
• WCIGMFCFPXZRMQ-UHFFFAOYSA-N 5-(2-fluoropyridin-4-yl)-2-phenylmethoxy-n-pyridin-3-ylbenzamide Chemical compound C1=NC(F)=CC(C=2C=C(C(OCC=3C=CC=CC=3)=CC=2)C(=O)NC=2C=NC=CC=2)=C1 WCIGMFCFPXZRMQ-UHFFFAOYSA-N 0.000 description 1
• 108091005482 5-HT4 receptors Proteins 0.000 description 1
• 108091005435 5-HT6 receptors Proteins 0.000 description 1
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
• 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• MYCCSWIILBRZKV-UHFFFAOYSA-N 6-azaspiro[2.5]octan-6-yl-(3-methoxy-4-nitrophenyl)methanone Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCC2(CC2)CC1)[N+]([O-])=O MYCCSWIILBRZKV-UHFFFAOYSA-N 0.000 description 1
• LERWQWRKAGZJMX-UHFFFAOYSA-N 6-azaspiro[2.5]octan-7-ylmethanol Chemical compound C1CC11CC(NCC1)CO LERWQWRKAGZJMX-UHFFFAOYSA-N 0.000 description 1
• NVZWMJWMTWOVNJ-UHFFFAOYSA-N 6-azaspiro[3.4]octane Chemical compound C1CCC21CNCC2 NVZWMJWMTWOVNJ-UHFFFAOYSA-N 0.000 description 1
• DNLMWWLLGMTQII-UHFFFAOYSA-N 6-chloro-4-ethoxy-1h-pyrazolo[3,4-d]pyrimidine Chemical compound CCOC1=NC(Cl)=NC2=C1C=NN2 DNLMWWLLGMTQII-UHFFFAOYSA-N 0.000 description 1
• DUMZNUKZTTUQQA-UHFFFAOYSA-N 6-chloro-4-ethoxy-3-methyl-2h-pyrazolo[3,4-d]pyrimidine Chemical compound CCOC1=NC(Cl)=NC2=NNC(C)=C12 DUMZNUKZTTUQQA-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• AFQMLHYSJLGTSO-OAQYLSRUSA-N C(C)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)C(=O)N1[C@H](CCC1)COC)OC)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 Chemical compound C(C)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)C(=O)N1[C@H](CCC1)COC)OC)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 AFQMLHYSJLGTSO-OAQYLSRUSA-N 0.000 description 1
• SXDPQGRNHSLZPC-ZJNRKIDTSA-N CNC(=O)C[C@@H]1C[C@H]([C@@H](CN1)NC(=O)c1cc(c(Cl)o1)-c1c(Cl)cnn1C)c1ccc(F)c(F)c1 Chemical compound CNC(=O)C[C@@H]1C[C@H]([C@@H](CN1)NC(=O)c1cc(c(Cl)o1)-c1c(Cl)cnn1C)c1ccc(F)c(F)c1 SXDPQGRNHSLZPC-ZJNRKIDTSA-N 0.000 description 1
• DVYOPEZFDVRESE-SNVBAGLBSA-N COC1=C(N)C=CC(=C1)C(=O)N1CCN(C)[C@H](C)C1 Chemical compound COC1=C(N)C=CC(=C1)C(=O)N1CCN(C)[C@H](C)C1 DVYOPEZFDVRESE-SNVBAGLBSA-N 0.000 description 1
• BNVRYZZCYNOIKT-UHFFFAOYSA-N COCC1CC11CCN(CC1)C(=O)C1=CC(OC)=C(N)C=C1 Chemical compound COCC1CC11CCN(CC1)C(=O)C1=CC(OC)=C(N)C=C1 BNVRYZZCYNOIKT-UHFFFAOYSA-N 0.000 description 1
• DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000000655 Distemper Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 239000001692 EU approved anti-caking agent Substances 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 229920002907 Guar gum Polymers 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 239000004233 Indanthrene blue RS Substances 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 1
• 102220578200 Leucine-rich repeat serine/threonine-protein kinase 2_G2385R_mutation Human genes 0.000 description 1
• 102220596659 Leucine-rich repeat serine/threonine-protein kinase 2_R1441H_mutation Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 102100027869 Moesin Human genes 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• KEOHLOIPFXSCQW-LBPRGKRZSA-N NC1=C(C=C(C=C1)C(=O)N1C[C@H]2N(CC1)CCC2)OC Chemical compound NC1=C(C=C(C=C1)C(=O)N1C[C@H]2N(CC1)CCC2)OC KEOHLOIPFXSCQW-LBPRGKRZSA-N 0.000 description 1
• 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
• 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 208000002192 Parkinson disease 3 Diseases 0.000 description 1
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
• 241000009328 Perro Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 102100022127 Radixin Human genes 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
• 108091006629 SLC13A2 Proteins 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 108010034546 Serratia marcescens nuclease Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 239000012505 Superdex™ Substances 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 208000032859 Synucleinopathies Diseases 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• 229940122777 Tau aggregation inhibitor Drugs 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• RACBJESQSVIGMZ-UHFFFAOYSA-N [2-(methoxymethyl)pyrrolidin-1-yl]methanone Chemical compound COCC1CCCN1[C]=O RACBJESQSVIGMZ-UHFFFAOYSA-N 0.000 description 1
• AFQMLHYSJLGTSO-NRFANRHFSA-N [4-[[4-ethoxy-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]methanone Chemical compound C(C)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)C(=O)N1[C@@H](CCC1)COC)OC)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 AFQMLHYSJLGTSO-NRFANRHFSA-N 0.000 description 1
• YGTVTCXPKCEENE-UHFFFAOYSA-N [4-amino-3-(dimethylamino)phenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound CN(C)C1=CC(=CC=C1N)C(=O)N1CCN(C)CC1 YGTVTCXPKCEENE-UHFFFAOYSA-N 0.000 description 1
• XQAXGZLFSSPBMK-UHFFFAOYSA-M [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride;trihydrate Chemical compound O.O.O.[Cl-].C1=CC(=[N+](C)C)C=C2SC3=CC(N(C)C)=CC=C3N=C21 XQAXGZLFSSPBMK-UHFFFAOYSA-M 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229940048053 acrylate Drugs 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
• 235000011114 ammonium hydroxide Nutrition 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 201000002783 amyotrophic lateral sclerosis type 12 Diseases 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000004642 autophagic pathway Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 125000005998 bromoethyl group Chemical group 0.000 description 1
• AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000004915 chaperone-mediated autophagy Effects 0.000 description 1
• 239000013522 chelant Substances 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960000913 crospovidone Drugs 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 150000001975 deuterium Chemical group 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000019700 dicalcium phosphate Nutrition 0.000 description 1
• 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
• 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 230000009429 distress Effects 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
• 229960003135 donepezil hydrochloride Drugs 0.000 description 1
• 229960003638 dopamine Drugs 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 238000001952 enzyme assay Methods 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
• MSYHIJNSNXQIQS-UHFFFAOYSA-N ethyl 6-azaspiro[2.5]octane-2-carboxylate Chemical compound CCOC(=O)C1CC11CCNCC1 MSYHIJNSNXQIQS-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 208000015756 familial Alzheimer disease Diseases 0.000 description 1
• 238000003818 flash chromatography Methods 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 230000005484 gravity Effects 0.000 description 1
• 239000000665 guar gum Substances 0.000 description 1
• 235000010417 guar gum Nutrition 0.000 description 1
• 229960002154 guar gum Drugs 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 239000003999 initiator Substances 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 229940116871 l-lactate Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 210000004901 leucine-rich repeat Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 230000006655 lysosomal degradation pathway Effects 0.000 description 1
• 230000004142 macroautophagy Effects 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 241001515942 marmosets Species 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000010197 meta-analysis Methods 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• AWUPLMYXZJKHEG-UHFFFAOYSA-N methyl 2-chloro-2,2-difluoroacetate Chemical compound COC(=O)C(F)(F)Cl AWUPLMYXZJKHEG-UHFFFAOYSA-N 0.000 description 1
• IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• 229960000907 methylthioninium chloride Drugs 0.000 description 1
• 230000002025 microglial effect Effects 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000006676 mitochondrial damage Effects 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 239000012046 mixed solvent Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 108010071525 moesin Proteins 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 239000003149 muscarinic antagonist Substances 0.000 description 1
• 238000001964 muscle biopsy Methods 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 210000002241 neurite Anatomy 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 208000018360 neuromuscular disease Diseases 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
• BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
• 229920002113 octoxynol Polymers 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 239000010502 orange oil Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 231100000255 pathogenic effect Toxicity 0.000 description 1
• 230000003950 pathogenic mechanism Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 208000024335 physical disease Diseases 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 239000013612 plasmid Substances 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 238000000634 powder X-ray diffraction Methods 0.000 description 1
• FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
• 229960003089 pramipexole Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000007112 pro inflammatory response Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000007111 proteostasis Effects 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 108010048484 radixin Proteins 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 229960004136 rivastigmine Drugs 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
• 229960001879 ropinirole Drugs 0.000 description 1
• 229940080817 rotenone Drugs 0.000 description 1
• JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000008786 sensory perception of smell Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 229920003109 sodium starch glycolate Polymers 0.000 description 1
• 239000008109 sodium starch glycolate Substances 0.000 description 1
• 229940079832 sodium starch glycolate Drugs 0.000 description 1
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 208000037100 susceptibility to 1 spondyloarthropathy Diseases 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
• 229960001685 tacrine Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• DATRVIMZZZVHMP-QMMMGPOBSA-N tert-butyl (2s)-2-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CNCCN1C(=O)OC(C)(C)C DATRVIMZZZVHMP-QMMMGPOBSA-N 0.000 description 1
• BTWDGFQQIGGAPU-UHFFFAOYSA-N tert-butyl 1-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2CC21CO BTWDGFQQIGGAPU-UHFFFAOYSA-N 0.000 description 1
• IGNPZIKVBPDVMR-UHFFFAOYSA-N tert-butyl 7-(hydroxymethyl)-6-azaspiro[2.5]octane-6-carboxylate Chemical compound C1C(CO)N(C(=O)OC(C)(C)C)CCC11CC1 IGNPZIKVBPDVMR-UHFFFAOYSA-N 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• 238000003354 tissue distribution assay Methods 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
• 230000004565 tumor cell growth Effects 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1